Be tough on people not disciplined: Bharat Biotech's Suchitra Ella
Ella was the company’s go-to person during the production of its indigenously developed Covid-19 vaccine, Covaxin—engaging with multiple ministries almost on a daily basis.
Ella was the company’s go-to person during the production of its indigenously developed Covid-19 vaccine, Covaxin—engaging with multiple ministries almost on a daily basis.
As India battles the second wave of Covid-19, which has caused havoc across the country, healthcare companies have come to the fore as lifesavers, to ensure the attack of the virus is countered.
The country’s daily requirement is over 10 million doses against the production of 2.9 million. The Sputnik V vaccine, which got the nod on Monday, will help bridge the gap, albeit marginally.
One of the issues with vaccine development is the enormous time required to produce one. The Covid-19 vaccine has shown the process can be expedited. But can the process be made even more faster?
Through a historic ‘vaccine diplomacy’ and embracing the Quad, India has sent its clearest signals that it has a new worldview.
With the Covid-19 vaccination drive entering phase 2 in India, it is important to emphasise the positive role the private sector can play in facilitating the vaccine's availability for the masses.
Prices of vaccines may crash in the next few months. The vaccine makers will have to strike while the iron is hot.
For long thought of as a net recipient of global health benefits, India is turning into a global healthcare provider. This will be a major pillar of its diplomacy in the years to come.
India began the first phase of the mass vaccination programme against Covid-19. Fortune India's photo team visited one session site in Gurugram where the campaign was in full swing.
For BBIL’s founder Krishna Ella, the roll-out of a made-in-India vaccine, Covaxin, is peppered with challenges. Two recent deals with Brazilian and American firms have now buoyed him.